Controlled Substances Act

The Controlled Substances Act (CSA) is a United States federal statute, enacted by Congress in 1970 as Title II of the Comprehensive Drug Abuse Prevention and Control Act. It created a single regulatory framework placing drugs and certain chemicals into five numbered schedules, organized around three criteria: potential for abuse, accepted medical use within the United States, and the likelihood of dependence if misused.

Schedule I — the most restrictive tier — requires a finding of high abuse potential, no currently accepted medical use in treatment, and a lack of accepted safety for use under medical supervision. Schedules II through V carry progressively lower restrictions as those criteria ease.

What it means in practice

The DEA administers the CSA; the FDA evaluates the medical and safety criteria that inform each scheduling decision. Changes to a substance's schedule move through notice-and-comment rulemaking. The statute also allows temporary emergency placement into Schedule I for up to two years without completing that process — a mechanism used frequently for novel synthetic compounds.

The schedule a substance occupies determines access. Schedule I substances cannot be prescribed; research on them requires a separate DEA registration with more stringent conditions than apply to Schedule II substances. Schedules II through V carry progressively lower restrictions on prescribing, dispensing, and handling.

The CSA also reaches beyond its named substance list through analogue provisions. A compound substantially similar in chemical structure or pharmacological effect to a Schedule I or II substance — if intended for human consumption — may be treated as a Schedule I substance under federal law, extending the statute's reach to compounds not yet subject to formal rulemaking.

How jurisdictions vary

The five-schedule structure is specific to the United States and does not map onto other countries' systems. The United Kingdom's Misuse of Drugs Act 1971 organises controlled substances into Classes A, B, and C. Canada operates its own Controlled Drugs and Substances Act. International treaties — including the 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances — use their own schedule structures, which do not correspond to the CSA's tiers.

A substance in CSA Schedule I may be available on prescription elsewhere, or unscheduled entirely. The schedule number carries no legal weight outside the United States.

What is contested

The phrase no currently accepted medical use functions as a legal conclusion under the CSA, not as a direct reading of the clinical literature. The statute's definition of that phrase involves criteria specific to federal regulatory practice and does not update automatically as trial data accumulates or as other regulatory bodies approve treatment indications.

This gap has produced documented divergences. The FDA has approved preparations derived from or related to Schedule I substances for specific indications while the parent compound remained at Schedule I. The FDA has also issued Breakthrough Therapy designations — reflecting preliminary clinical evidence of substantial improvement over existing therapy — for investigational compounds whose parent substances hold Schedule I status. The two determinations are made under separate statutory processes and do not automatically resolve against each other.

Scope and currency

This entry describes what the Controlled Substances Act is and how it operates as a federal regulatory instrument. It is not legal advice and does not state the law as it applies to any individual or jurisdiction. Scheduling status can change through agency rulemaking, court decisions, or legislation; individual states may create conditions that differ from federal enforcement priorities. This entry states the position as of August 2026. For per-substance legal status — with jurisdiction, date, and source — consult the legal status section on each substance's page.